Neffy® (brand name: epinephrine nasal spray)
Manufacturer: ARS Pharmaceuticals
Launch Date: 09/23/2024
Neffy® (epinephrine nasal spray) was approved on August 9, 2024, for the emergency treatment of allergic reactions (type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients weighing at least 66 pounds. Neffy is available as a 2 mg single-dose nasal spray administered into one nostril.
Clinical Profile:
For decades Epinephrine has been a cornerstone in the emergency treatment of serious allergic reactions, traditionally available only in subcutaneous (injected under the skin) formulations. Neffy is the first non-injected formulation, offering ease of use and a longer expiration date.
Population:
It is important to note that neffy is currently only approved for adults & older pediatric patients (at least 66 lbs / 30 kgs). The manufacturer has filed a supplemental New Drug Application (sNDA) to expand approval to children weighing 33 lbs / 15 kg and above, with a decision expected in mid-2025.
Management Strategy:
Neffy is currently tiered as a non-preferred brand product on the ClearScript formulary with no prior authorization (PA) or step therapy (ST) required. This strategy is intended to favor lower-cost generic subcutaneous products while ensuring there are no unnecessary barriers for members who may need access to a more appropriate lifesaving product.
ClearScript will closely monitor developments and offer cost-containment strategies that align with your plan goals. Your ClearScript Account Team will keep you informed of opportunities as the market evolves.
Contact your ClearScript Clinical Account Executive with questions.
References
Additional Information
Press Release